Latest & greatest articles for parkinson

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on parkinson or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on parkinson and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for parkinson

1. Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study

Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study 30381367 2018 11 27 1526-632X 91 22 2018 Nov 27 Neurology Neurology Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study. e2045-e2056 10.1212/WNL.0000000000006576 To examine mortality and associated risk factors, including possible effects of mild cognitive impairment, imaging, and CSF abnormalities, in a community-based population with incident parkinsonism (...) and Parkinson disease. One hundred eighty-two patients with new-onset, idiopathic parkinsonism were diagnosed from January 2004 through April 2009, in a catchment area of 142,000 inhabitants in Sweden. Patients were comprehensively investigated according to a multimodal research protocol and followed prospectively for up to 13.5 years. A total of 109 patients died. Mortality rates in the general Swedish population were used to calculate standardized mortality ratio and expected survival, and Cox

EvidenceUpdates2018

2. ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease

‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease Signal - ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease Dissemination Centre Discover Portal NIHR DC Discover ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease Published on 23 March 2016 Physiotherapy and occupational therapy do (...) not help people with mild to moderate Parkinson’s disease to lead more independent lives. This NIHR-funded randomised controlled trial of adults with Parkinson’s disease did not find any difference between the therapy group and a no-therapy control group at up to 15 months in any of the four measures of activities of daily living: mobility, kitchen activities, domestic tasks or leisure activities. The average ‘dose’ of the therapies was four sessions of 58 minutes over eight weeks for both therapies

NIHR Dissemination Centre2018

3. Cost-effectiveness of the HiBalance training program for elderly with Parkinson`s disease: analysis of data from a randomized controlled trial

Cost-effectiveness of the HiBalance training program for elderly with Parkinson`s disease: analysis of data from a randomized controlled trial 30246557 2018 09 24 1477-0873 2018 Sep 24 Clinical rehabilitation Clin Rehabil Cost-effectiveness of the HiBalance training program for elderly with Parkinson's disease: analysis of data from a randomized controlled trial. 269215518800832 10.1177/0269215518800832 To determine the cost-effectiveness of the HiBalance training program for managing (...) Parkinson's disease (PD)-related balance and gait disorders. Cost comparison design following the randomized controlled trial comparing a novel balance training intervention with care as usual. A total of 100 participants with mild-moderate PD were randomized to either the intervention ( n = 51) or the control group ( n = 49). A 10-week (three times per week), group-based, progressive balance training program, led by two physical therapists. All program costs were collected for both groups. Cost-utility

EvidenceUpdates2018

4. Parkinson Disease.

Parkinson Disease. Parkinson disease is a common neurodegenerative disorder that causes progressive motor and nonmotor disability. It is diagnosed clinically and requires a detailed history and neurologic examination to exclude alternative diagnoses. Although disease-modifying therapies do not exist for Parkinson disease, effective symptomatic therapies, including dopaminergic medications and surgery, allow patients to maintain good quality of life for many years. Nonmotor symptoms, including

Annals of Internal Medicine2018

5. Long-term effects of highly challenging balance training in Parkinson's disease-a randomized controlled trial

Long-term effects of highly challenging balance training in Parkinson's disease-a randomized controlled trial 29962227 2018 07 02 1477-0873 2018 Jun 01 Clinical rehabilitation Clin Rehabil Long-term effects of highly challenging balance training in Parkinson's disease-a randomized controlled trial. 269215518784338 10.1177/0269215518784338 To determine long-term effects of a highly challenging training program in people with Parkinson's disease, as well as describe how initially observed (...) improvements of the program deteriorated over time. Long-term follow-up of previously reported outcomes at 10 weeks of a randomized controlled trial. University hospital setting. One-hundred elderly with mild-to-moderate (Hoehn and Yahr 2-3) Parkinson's disease. Participants in the training group ( n = 51) received 10 weeks (three times/week) of balance and gait exercises, incorporating dual-tasks, while the control group ( n = 49) received care as usual. Balance control (Mini-Balance Evaluation System

EvidenceUpdates2018

6. Parkinson?s disease

Parkinson?s disease Top results for parkinson's disease - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for parkinson's disease The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

7. Non-pharmacological therapies for sleep disturbances in people with Parkinson's disease: A systematic review

Non-pharmacological therapies for sleep disturbances in people with Parkinson's disease: A systematic review 29700848 2018 05 31 1365-2648 2018 Apr 27 Journal of advanced nursing J Adv Nurs Non-pharmacological therapies for sleep disturbances in people with Parkinson's disease: A systematic review. 10.1111/jan.13694 To determine the effectiveness of non-pharmacological therapies for sleep disturbances in people with Parkinson's disease (PD). Sleep disturbances, which are common in people (...) . Journal of Advanced Nursing Published by John Wiley & Sons Ltd. Lee JuHee J http://orcid.org/0000-0002-2805-1622 Mo-Im Kim Nursing Research Institute, College of Nursing, Yonsei University, Seoul, Korea. Kim Yonji Y Graduate School, College of Nursing, Yonsei University, Seoul, Korea. Kim Yie Lin YL Graduate School, College of Nursing, Yonsei University, Seoul, Korea. eng Journal Article Review 2018 04 27 England J Adv Nurs 7609811 0309-2402 Parkinson's disease non-pharmacological sleep systematic

EvidenceUpdates2018

8. Parkinson's disease

Parkinson's disease Autosynthesis - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing

Trip Evidence Maps2018

9. Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014

Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014 29785965 2018 05 22 1468-3288 2018 May 21 Gut Gut Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014. gutjnl-2017-315666 10.1136/gutjnl-2017-315666 Intestinal inflammation has been suggested to play a role in development of Parkinson's disease (PD) and multiple system atrophy (MSA). To test the hypothesis that IBD is (...) of PD as compared with non-IBD individuals (HR=1.22; 95% CI 1.09 to 1.35). The increased risk was present independently of age at IBD diagnosis, gender or length of follow-up. The overall incidence of MSA was low in our study, and the regression analysis suggested a tendency towards higher risk of developing MSA in patients with IBD as compared with non-IBD individuals (HR=1.41; 95% CI 0.82 to 2.44). Estimates were similar for women and men. The increased risk of parkinsonism was significantly

EvidenceUpdates2018

10. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients with Parkinson?s Disease

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients with Parkinson?s Disease

Congress of Neurological Surgeons2018

11. The Effects of Functional Training, Bicycle Exercise, and Exergaming on Walking Capacity of Elderly Patients With Parkinson Disease: A Pilot Randomized Controlled Single-blinded Trial

The Effects of Functional Training, Bicycle Exercise, and Exergaming on Walking Capacity of Elderly Patients With Parkinson Disease: A Pilot Randomized Controlled Single-blinded Trial 29337023 2018 04 27 1532-821X 99 5 2018 May Archives of physical medicine and rehabilitation Arch Phys Med Rehabil The Effects of Functional Training, Bicycle Exercise, and Exergaming on Walking Capacity of Elderly Patients With Parkinson Disease: A Pilot Randomized Controlled Single-blinded Trial. 826-833 S0003 (...) -9993(18)30009-1 10.1016/j.apmr.2017.12.014 To compare the effects of functional training, bicycle exercise, and exergaming on walking capacity of elderly with Parkinson disease (PD). A pilot randomized, controlled, single-blinded trial. A state reference health care center for elderly, a public reference outpatient clinic for the elderly. Elderly individuals (≥60 years of age; N=62) with idiopathic PD (stage 2 to 3 of modified Hoehn and Yahr staging scale) according to the London Brain Bank

EvidenceUpdates2018

12. ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease

‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease NIHR DC | Signal - ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease Published on 23 March 2016 Physiotherapy and (...) occupational therapy do not help people with mild to moderate Parkinson’s disease to lead more independent lives. This NIHR-funded randomised controlled trial of adults with Parkinson’s disease did not find any difference between the therapy group and a no-therapy control group at up to 15 months in any of the four measures of activities of daily living: mobility, kitchen activities, domestic tasks or leisure activities. The average ‘dose’ of the therapies was four sessions of 58 minutes over eight weeks

NIHR Dissemination Centre2018

13. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial

Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial 29452685 2018 03 01 1474-4465 17 3 2018 Mar The Lancet. Neurology Lancet Neurol Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis (...) of an open-label randomised trial. 223-231 S1474-4422(18)30035-8 10.1016/S1474-4422(18)30035-8 Although subthalamic stimulation is a recognised treatment for motor complications in Parkinson's disease, reports on behavioural outcomes are controversial, which represents a major challenge when counselling candidates for subthalamic stimulation. We aimed to assess changes in behaviour in patients with Parkinson's disease receiving combined treatment with subthalamic stimulation and medical therapy over a 2

EvidenceUpdates2018

14. Levodopa-carbidopa intestinal gel (Duodopa) - Parkinson?s disease

Levodopa-carbidopa intestinal gel (Duodopa) - Parkinson?s disease %PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��\Yo�Ȳ~7���G��f�$Y&�9�����Crh�����ђ��S�7ު�E�ZVlz.G"�]]]]���MEW�����/����:z��Ut��FGw�ˋ?//T�)���' T���*fr�E2��bt2�/��`�z(+�yM��@h��J �o� ZW[�(R�z�(O��(�ڼ�&���AKԫ��ɇ6�������vȯ��9��*�%��V���(2m��)��I3��s���~�y

All Wales Medicines Strategy Group2018

15. Efficacy of intensive multidisciplinary rehabilitation in Parkinson's disease: a randomised controlled study

Efficacy of intensive multidisciplinary rehabilitation in Parkinson's disease: a randomised controlled study 29321141 2018 02 07 1468-330X 2018 Jan 10 Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatry Efficacy of intensive multidisciplinary rehabilitation in Parkinson's disease: a randomised controlled study. jnnp-2017-316437 10.1136/jnnp-2017-316437 To evaluate whether a 4-week multidisciplinary, aerobic, motor-cognitive and intensive rehabilitation treatment (...) (MIRT) improves the quality of life (QoL) of patients with Parkinson's disease (PD), in the short-term and long-term period. This is a prospective, parallel-group, single-centre, single-blind, randomised clinical trial (ClinicalTrials.gov NCT02756676). 186 patients with PD, assigned to experimental group, underwent MIRT; conversely, 48 patients, assigned to control group, did not receive rehabilitation. Parkinson's Disease Questionnaire-39 was assessed 2 (T0), 10 (T1) and 18 (T2, only experimental

EvidenceUpdates2018

18. The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease

The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease 30009211 2018 11 14 2330-1619 5 2 2018 Mar-Apr Movement disorders clinical practice Mov Disord Clin Pract The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease. 171-176 10.1002/mdc3.12591 Rapid eye movement (REM) sleep behavior disorder (RBD) is one of the most specific prodromal indicators for Parkinson's disease (PD). To test the validity of the RBD (...) Neurol Neurosurg Psychiatry. 2002 Dec;73(6):629-35 12438461 Neurology. 2009 Feb 10;72(6):551-7 19204265 Sleep Med. 2015 Jan;16(1):186-9 25534709 Mov Disord. 2007 Dec;22(16):2386-93 17894337 Mov Disord. 2011 Mar;26(4):644-52 21312275 Neurology. 2016 Jul 12;87(2):168-77 27164658 Sleep. 2014 Mar 01;37(3):431-8 24587564 Neurology. 2013 Oct 1;81(14):1226-34 23997153 Sleep. 2012 Jun 01;35(6):835-47 22654203 Sleep. 2016 Sep 01;39(9):1737-42 27306265 Parkinsonism Relat Disord. 2014 Jul;20(7):766-71 24787758

Movement disorders clinical practice2018 Full Text: Link to full Text with Trip Pro

19. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102 29780852 2018 11 14 2330-1619 5 2 2018 Mar-Apr Movement disorders clinical practice Mov Disord Clin Pract Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102. 183-190 10.1002/mdc3.12595 ADS-5102 (amantadine) extended release capsules (GOCOVRI™) are a treatment for dyskinesia in patients with Parkinson's disease (PD). ADS-5102 reduced (...) by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV. This manuscript focuses on those patients switched to ADS-5102 from amantadine IR. Results in two groups of patients who previously completed a randomized controlled trial (EASE LID or EASE LID 3) are also presented according to use of ADS-5102 or placebo in that study before enrollment in the open-label study. Change in MDS-UPDRS Part IV at week 8 was -0.3 in the previous ADS-5102 subgroup ( n = 61), -3.4

Movement disorders clinical practice2018 Full Text: Link to full Text with Trip Pro

20. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized, double-blind phase 2 study

Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized, double-blind phase 2 study 29367449 2018 02 22 1526-632X 90 8 2018 Feb 20 Neurology Neurology Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study. e664-e672 10.1212/WNL.0000000000005010 To investigate the efficacy and safety of zonisamide as an adjunct to levodopa therapy for parkinsonism in patients with dementia with Lewy bodies (DLB). This phase 2, placebo-controlled, randomized (...) , double-blind study consisted of run-in (placebo, 4 weeks) and treatment (placebo or zonisamide 25 or 50 mg once daily, 12 weeks) periods. Outpatients diagnosed with probable DLB were eligible for inclusion. The primary endpoint was the change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS) part 3 total score at week 12. Cognitive function, behavioral and psychological symptoms of dementia (BPSD), caregiver burden, other UPDRS parts as secondary endpoints, and safety were also

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro